Taken together, these results show that the EZH2 expression is negatively correlated with PIK3IP1 in newly diagnosed AML patients, and an EZH2-high expression is associated with poor outcomes in AML patients. This evidence concerns the gene EZH2 and acute myeloid leukemia.